Home › Trials › NCT02834884

Screening cancer patients for better access to clinical trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Observational European Organisation for Research and Treatment of Cancer - EORTC · NCT02834884

This study is trying to see if collecting detailed information and samples from cancer patients can help improve access to clinical trials and enhance cancer treatment.

Quick facts

Study typeObservational
Enrollment4975 (estimated)
Ages12 Years and up
SexAll
SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC Research network
Locations134 sites (Vienna and 133 other locations)
Trial IDNCT02834884 on ClinicalTrials.gov

What this trial studies

SPECTA is a platform designed to collect various biological materials and data from cancer patients to enhance translational research and clinical studies. It focuses on gathering clinicopathological information, imaging data, and patient-reported outcomes to support biomarker discovery and improve cancer care. Patients are recruited for multiple downstream projects that utilize this comprehensive data for research purposes.

Who should consider this trial

Good fit: Ideal candidates include patients aged 12 and older with pathologically confirmed tumor types and adequate biological material available.

Not a fit: Patients with psychological, familial, sociological, or geographical issues that may hinder compliance with the study protocol may not benefit from this study.

Why it matters

Potential benefit: If successful, this initiative could significantly improve the understanding of tumor biology and enhance treatment options for cancer patients.

How similar studies have performed: Other studies utilizing similar biomarker and data collection approaches have shown promise in advancing cancer research.

Eligibility criteria

Show full inclusion / exclusion criteria 
* Patients with pathologically confirmed selected tumor types (at site or centrally);
* Mandatory availability of adequate human biological material (HBM);
* Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
* Age ≥ 12 years;
* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
* Written informed consent according to applicable legal and ethical requirements;

Where this trial is running

Vienna and 133 other locations

+84 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions All Tumor Typesrare cancerbiomarkermolecular screeningcancerbiobanking
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.